Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins

Scott Thomson, Matthew L. Edin, Fred B. Lih, Michael Davies, Muhammad M. Yaqoob, Bruce D. Hammock, Derek Gilroy, Darryl C. Zeldin, David Bishop-Bailey

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Vascular pathologies are associated with changes in the presence and expression of morphologically distinct vascular smooth muscle cells. In particular, in complex human vascular lesions and models of disease in pigs and rodents, an intimal smooth muscle cell (iSMC) which exhibits a stable epithelioid or rhomboid phenotype in culture is often found to be present in high numbers, and may represent the reemergence of a distinct developmental vascular smooth muscle cell phenotype. The CYP450-oxylipin - soluble epoxide hydrolase (sEH) pathway is currently of great interest in targeting for cardiovascular disease. sEH inhibitors limit the development of hypertension, diabetes, atherosclerosis and aneurysm formation in animal models. We have investigated the expression of CYP450-oxylipin-sEH pathway enzymes and their metabolites in paired intimal (iSMC) and medial (mSMC) cells isolated from rat aorta. iSMC basally released significantly larger amounts of epoxy-oxylipin CYP450 products from eicosapentaenoic acid > docosahexaenoic acid > arachidonic acid > linoleic acid, and expressed higher levels of CYP2C12, CYP2B1, but not CYP2J mRNA compared to mSMC. When stimulated with the pro-inflammatory TLR4 ligand LPS, epoxy-oxylipin production did not change greatly in iSMC. In contrast, LPS induced epoxy-oxylipin products in mSMC and induced CYP2J4. iSMC and mSMC express sEH which metabolizes primary epoxy-oxylipins to their dihydroxy-counterparts. The sEH inhibitors TPPU or AUDA inhibited LPS-induced NFκB activation and iNOS induction in mSMC, but had no effect on NFκB nuclear localization or inducible nitric oxide synthase in iSMC; effects which were recapitulated in part by addition of authentic epoxy-oxylipins. iSMCs are a rich source but not a sensor of anti-inflammatory epoxy-oxylipins. Complex lesions that contain high levels of iSMCs may be more resistant to the protective effects of sEH inhibitors.

Original languageEnglish (US)
Pages (from-to)774-780
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume463
Issue number4
DOIs
StatePublished - May 27 2015
Externally publishedYes

Fingerprint

Oxylipins
Tunica Intima
Epoxide Hydrolases
Smooth Muscle Myocytes
Muscle
Anti-Inflammatory Agents
Cells
Sensors
Vascular Smooth Muscle
Blood Vessels
Cytochrome P-450 CYP2B1
Phenotype
Eicosapentaenoic Acid
Docosahexaenoic Acids
Nitric Oxide Synthase Type II
Pathology
Linoleic Acid
Medical problems
Metabolites
Arachidonic Acid

Keywords

  • Epoxygenase
  • LPS
  • Oxylipin
  • Smooth muscle cell
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Thomson, S., Edin, M. L., Lih, F. B., Davies, M., Yaqoob, M. M., Hammock, B. D., ... Bishop-Bailey, D. (2015). Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins. Biochemical and Biophysical Research Communications, 463(4), 774-780. https://doi.org/10.1016/j.bbrc.2015.06.012

Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins. / Thomson, Scott; Edin, Matthew L.; Lih, Fred B.; Davies, Michael; Yaqoob, Muhammad M.; Hammock, Bruce D.; Gilroy, Derek; Zeldin, Darryl C.; Bishop-Bailey, David.

In: Biochemical and Biophysical Research Communications, Vol. 463, No. 4, 27.05.2015, p. 774-780.

Research output: Contribution to journalArticle

Thomson, S, Edin, ML, Lih, FB, Davies, M, Yaqoob, MM, Hammock, BD, Gilroy, D, Zeldin, DC & Bishop-Bailey, D 2015, 'Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins', Biochemical and Biophysical Research Communications, vol. 463, no. 4, pp. 774-780. https://doi.org/10.1016/j.bbrc.2015.06.012
Thomson, Scott ; Edin, Matthew L. ; Lih, Fred B. ; Davies, Michael ; Yaqoob, Muhammad M. ; Hammock, Bruce D. ; Gilroy, Derek ; Zeldin, Darryl C. ; Bishop-Bailey, David. / Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins. In: Biochemical and Biophysical Research Communications. 2015 ; Vol. 463, No. 4. pp. 774-780.
@article{253717a2de9e48a48da598d9a5cdb67c,
title = "Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins",
abstract = "Vascular pathologies are associated with changes in the presence and expression of morphologically distinct vascular smooth muscle cells. In particular, in complex human vascular lesions and models of disease in pigs and rodents, an intimal smooth muscle cell (iSMC) which exhibits a stable epithelioid or rhomboid phenotype in culture is often found to be present in high numbers, and may represent the reemergence of a distinct developmental vascular smooth muscle cell phenotype. The CYP450-oxylipin - soluble epoxide hydrolase (sEH) pathway is currently of great interest in targeting for cardiovascular disease. sEH inhibitors limit the development of hypertension, diabetes, atherosclerosis and aneurysm formation in animal models. We have investigated the expression of CYP450-oxylipin-sEH pathway enzymes and their metabolites in paired intimal (iSMC) and medial (mSMC) cells isolated from rat aorta. iSMC basally released significantly larger amounts of epoxy-oxylipin CYP450 products from eicosapentaenoic acid > docosahexaenoic acid > arachidonic acid > linoleic acid, and expressed higher levels of CYP2C12, CYP2B1, but not CYP2J mRNA compared to mSMC. When stimulated with the pro-inflammatory TLR4 ligand LPS, epoxy-oxylipin production did not change greatly in iSMC. In contrast, LPS induced epoxy-oxylipin products in mSMC and induced CYP2J4. iSMC and mSMC express sEH which metabolizes primary epoxy-oxylipins to their dihydroxy-counterparts. The sEH inhibitors TPPU or AUDA inhibited LPS-induced NFκB activation and iNOS induction in mSMC, but had no effect on NFκB nuclear localization or inducible nitric oxide synthase in iSMC; effects which were recapitulated in part by addition of authentic epoxy-oxylipins. iSMCs are a rich source but not a sensor of anti-inflammatory epoxy-oxylipins. Complex lesions that contain high levels of iSMCs may be more resistant to the protective effects of sEH inhibitors.",
keywords = "Epoxygenase, LPS, Oxylipin, Smooth muscle cell, Soluble epoxide hydrolase",
author = "Scott Thomson and Edin, {Matthew L.} and Lih, {Fred B.} and Michael Davies and Yaqoob, {Muhammad M.} and Hammock, {Bruce D.} and Derek Gilroy and Zeldin, {Darryl C.} and David Bishop-Bailey",
year = "2015",
month = "5",
day = "27",
doi = "10.1016/j.bbrc.2015.06.012",
language = "English (US)",
volume = "463",
pages = "774--780",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins

AU - Thomson, Scott

AU - Edin, Matthew L.

AU - Lih, Fred B.

AU - Davies, Michael

AU - Yaqoob, Muhammad M.

AU - Hammock, Bruce D.

AU - Gilroy, Derek

AU - Zeldin, Darryl C.

AU - Bishop-Bailey, David

PY - 2015/5/27

Y1 - 2015/5/27

N2 - Vascular pathologies are associated with changes in the presence and expression of morphologically distinct vascular smooth muscle cells. In particular, in complex human vascular lesions and models of disease in pigs and rodents, an intimal smooth muscle cell (iSMC) which exhibits a stable epithelioid or rhomboid phenotype in culture is often found to be present in high numbers, and may represent the reemergence of a distinct developmental vascular smooth muscle cell phenotype. The CYP450-oxylipin - soluble epoxide hydrolase (sEH) pathway is currently of great interest in targeting for cardiovascular disease. sEH inhibitors limit the development of hypertension, diabetes, atherosclerosis and aneurysm formation in animal models. We have investigated the expression of CYP450-oxylipin-sEH pathway enzymes and their metabolites in paired intimal (iSMC) and medial (mSMC) cells isolated from rat aorta. iSMC basally released significantly larger amounts of epoxy-oxylipin CYP450 products from eicosapentaenoic acid > docosahexaenoic acid > arachidonic acid > linoleic acid, and expressed higher levels of CYP2C12, CYP2B1, but not CYP2J mRNA compared to mSMC. When stimulated with the pro-inflammatory TLR4 ligand LPS, epoxy-oxylipin production did not change greatly in iSMC. In contrast, LPS induced epoxy-oxylipin products in mSMC and induced CYP2J4. iSMC and mSMC express sEH which metabolizes primary epoxy-oxylipins to their dihydroxy-counterparts. The sEH inhibitors TPPU or AUDA inhibited LPS-induced NFκB activation and iNOS induction in mSMC, but had no effect on NFκB nuclear localization or inducible nitric oxide synthase in iSMC; effects which were recapitulated in part by addition of authentic epoxy-oxylipins. iSMCs are a rich source but not a sensor of anti-inflammatory epoxy-oxylipins. Complex lesions that contain high levels of iSMCs may be more resistant to the protective effects of sEH inhibitors.

AB - Vascular pathologies are associated with changes in the presence and expression of morphologically distinct vascular smooth muscle cells. In particular, in complex human vascular lesions and models of disease in pigs and rodents, an intimal smooth muscle cell (iSMC) which exhibits a stable epithelioid or rhomboid phenotype in culture is often found to be present in high numbers, and may represent the reemergence of a distinct developmental vascular smooth muscle cell phenotype. The CYP450-oxylipin - soluble epoxide hydrolase (sEH) pathway is currently of great interest in targeting for cardiovascular disease. sEH inhibitors limit the development of hypertension, diabetes, atherosclerosis and aneurysm formation in animal models. We have investigated the expression of CYP450-oxylipin-sEH pathway enzymes and their metabolites in paired intimal (iSMC) and medial (mSMC) cells isolated from rat aorta. iSMC basally released significantly larger amounts of epoxy-oxylipin CYP450 products from eicosapentaenoic acid > docosahexaenoic acid > arachidonic acid > linoleic acid, and expressed higher levels of CYP2C12, CYP2B1, but not CYP2J mRNA compared to mSMC. When stimulated with the pro-inflammatory TLR4 ligand LPS, epoxy-oxylipin production did not change greatly in iSMC. In contrast, LPS induced epoxy-oxylipin products in mSMC and induced CYP2J4. iSMC and mSMC express sEH which metabolizes primary epoxy-oxylipins to their dihydroxy-counterparts. The sEH inhibitors TPPU or AUDA inhibited LPS-induced NFκB activation and iNOS induction in mSMC, but had no effect on NFκB nuclear localization or inducible nitric oxide synthase in iSMC; effects which were recapitulated in part by addition of authentic epoxy-oxylipins. iSMCs are a rich source but not a sensor of anti-inflammatory epoxy-oxylipins. Complex lesions that contain high levels of iSMCs may be more resistant to the protective effects of sEH inhibitors.

KW - Epoxygenase

KW - LPS

KW - Oxylipin

KW - Smooth muscle cell

KW - Soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=84936985344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936985344&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2015.06.012

DO - 10.1016/j.bbrc.2015.06.012

M3 - Article

VL - 463

SP - 774

EP - 780

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -